NCT06230328|Completed
Brazilian Reality of Hepatocellular Carcinoma
BRA-HEP
Loading search results
BRA-HEP
Sponsor study identifier
Secondary identifiers
OTHER · Hospital Israelita Albert Einstein
observational
300
1 country
11
Study Start
April 15, 2024
Actual (reported)Primary Completion
November 14, 2024
Actual (reported)Study Completion
November 14, 2024
Actual (reported)National, multicenter, retrospective, non-randomized observational study (Real World Evidence-RWE) with the purpose of analyzing the epidemiological profile of Hepatocellular Carcinomas (BCLC A, B or C), clinical management, progression profile and overall survival of castrated patients treated in national oncology care reference centers, within the last 6 years (between 2017 to 2022).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 14, 2024
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 22, 2023
Actual (reported)January 30, 2024
Actual (reported)April 15, 2024
Actual (reported)November 14, 2024
Actual (reported)November 14, 2024
Actual (reported)Epidemiological profile and pathological staging
Identify the epidemiological profile and pathological staging of patients diagnosed with hepatocellular carcinoma treated at participating centers. Describe the treatments adopted and the response to the progression or non-progression of the disease.
At first diagnosis and over 6 years (Time of retrospective observational analysis of the study)
Description of clinical condition
At first diagnosis and over 6 years (Time of retrospective observational analysis of the study)
Patients with early tumors at diagnosis (BCLC 0, A or B)
Pacientes com tumores avançados ao diagnóstico (BCLC C ou D)
Participants with a hepatocellular carcinoma diagnosis (early and intermediate), meeting the eligibility criteria, who have had a 1st time visit to the study sites between 2017 and 2022, and with at least 2 visits with accessible information in the medical record will be included.
Research Site
Barretos, Brazil
Research Site
Belo Horizonte, Brazil
Research Site
Curitiba, Brazil
Research Site
Natal, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Recife, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Diniz Gomes Bugano D, Batista EC, Fernandes I, Sanches Faria Pinto G, Fiorin de Vasconcellos V, Cembranelli Teixeira R, Cunha Sousa Oliveira S, Kruschewsky Coutinho Araujo A, Lopes Ponte de Souza A, Cordeiro Felismino T, Fernando Weschenfelder R, Pedro Guedes Camandaroba M, Pereira M, Miranda Duarte F, Lopes da Silva M, Andrade de Souza V, Gabriely Costa Oliveira I, Dos Santos Sampaio B, Regina Lamas Assis S, Prado Dos Santos G, Monfardini F, Duarte Fagundes Moia D, Soares R, Vicente Rizzo L, Reis Alvares da Silva M. Real-World Epidemiology, Treatment Patterns, and Outcomes of Hepatocellular Carcinoma in Brazil: A Multicenter Retrospective Study. JCO Glob Oncol. 2026 Jun;12(6):e2500526. doi: 10.1200/GO-25-00526. Epub 2026 Jun 24.
Diogo Bugano
Hospital Israelita Albert Einstein
300 participants (actual enrollment reported by the registry).
First Submitted
December 22, 2023
First Posted
January 30, 2024
Study Start
April 15, 2024
Actual (reported)Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Contact the study team to confirm eligibility.
Salvador, Brazil
Research Site
São Bernardo do Campo, Brazil
Research Site
São Paulo, Brazil
Research Site
Vitória, Brazil
Primary Completion
November 14, 2024
Actual (reported)Study Completion
November 14, 2024
Actual (reported)Last Updated
September 29, 2025
Record last verified: 2025-09
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: